Eton Pharmaceuticals stock reports 99 percent Q2 revenue growth

Eton Pharmaceuticals stock stood at USD 55.61 on Nasdaq on September 23, 2026, down 2.59 percent from the previous close. The company reported 99 percent year-over-year revenue growth for the second quarter of 2026, giving the rare disease specialist a sharply improved earnings profile.

Q2 revenue reaches USD 37.59 million

In results dated August 13, 2026, Simply Wall St reported Q2 revenue of USD 37.59 million and net income of USD 11.58 million. Diluted earnings per share reached USD 0.35, compared with a loss in the prior-year period.

The revenue figure also exceeded the USD 27.11 million consensus estimate by USD 10.48 million, or 38.7 percent, according to MarketBeat. That comparison matters because the company is combining revenue expansion with positive operating leverage rather than relying only on pipeline expectations.

Guidance sets a higher bar

Eton raised its 2026 annual revenue guidance to at least USD 145 million, while the Q2 result established USD 37.59 million as the latest quarterly revenue base. The guidance therefore implies that the company expects additional sales contribution during the remaining 2026 reporting periods.

Eton develops and commercializes treatments for rare diseases. Its portfolio includes eleven commercial rare disease products and five additional late-stage candidates, according to GlobeNewswire. The breadth of that portfolio gives investors a concrete operating metric to track beyond quarterly earnings: whether new products add to the USD 145 million revenue target.

Stock remains below its yearly high

At USD 55.61 on Nasdaq on September 23, 2026, ETON was USD 10.76 below its 52-week high of USD 66.37 and USD 41.34 above its 52-week low of USD 14.27. The market capitalization was USD 1,523,289,028 on the same date.